Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.44 |
| ▸ | MMP3 | P08254 | 11/20 | 0.44 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | Q9HBH1 | 1/20 | 0.43 | |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883757 | 0.92 | MMP3 (0.48) | MMP2MMP3MMP1MMP7PDF | |
| SCHEMBL4885026 | 0.90 | MMP13 (0.42) | MMP2MMP3MMP1EPHX2CCR8 | |
| SCHEMBL4880585 | 0.87 | MMP3 (0.42) | MMP2MMP3MMP1HTR1AHTR7 | |
| SCHEMBL4886950 | 0.78 | MMP13 (0.48) | EPHX2HTR1AHTR7 | |
| SCHEMBL4884939 | 0.77 | MMP3 (0.52) | MMP2MMP3MMP1MMP7PDF | |
| Hydrochloric Acid SCHEMBL4881432 | 0.73 | DPP4 (0.49) | EPHX2HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL4881423 | 0.73 | DPP4 (0.49) | EPHX2HTR1AHTR7 | |
| SCHEMBL4604487 | 0.72 | KMT2A (0.41) | MMP2MMP3PDF | |
| SCHEMBL4885918 | 0.72 | MMP2 (0.59) | MMP2MMP3MMP1 | |
| SCHEMBL4876342 | 0.71 | MMP2 (0.63) | MMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | MMP2 315/4885MMP3 362/4885MMP1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.